Autolus Q2 revenue up 119% to $45.7M; FY26 guidance raised to $140-150M

Autolus Therapeutics plc

Q2 2026 net product revenue $45.7M vs $20.9M YoY (+119%); Q1 2026 was $26.2M.
Gross margin jumped to 55% in Q2 from 6% in Q1 2026 on higher volumes and cost cuts.
Net loss narrowed to $39.1M ($0.15/sh) from $47.9M ($0.18/sh) in Q2 2025.
Closed $75M tranche of up to $250M five-year interest-only Perceptive Advisors credit facility.
Workforce reduction ~13% to save ~$15M annual opex; cash $201.6M at June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.